Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MDWD 
Mediwound Ltd (MDWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: MDWD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.39% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.78M USD | Price to earnings Ratio - | 1Y Target Price 30.67 |
Price to earnings Ratio - | 1Y Target Price 30.67 | ||
Volume (30-day avg) 75501 | Beta 0.3 | 52 Weeks Range 12.78 - 24.00 | Updated Date 06/18/2025 |
52 Weeks Range 12.78 - 24.00 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-05-27 | When Before Market | Estimate -0.662 | Actual -0.07 |
Profitability
Profit Margin -110.45% | Operating Margin (TTM) -132.11% |
Management Effectiveness
Return on Assets (TTM) -19.88% | Return on Equity (TTM) -77.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 181934820 | Price to Sales(TTM) 11.13 |
Enterprise Value 181934820 | Price to Sales(TTM) 11.13 | ||
Enterprise Value to Revenue 9.47 | Enterprise Value to EBITDA -6.32 | Shares Outstanding 10807700 | Shares Floating 7695421 |
Shares Outstanding 10807700 | Shares Floating 7695421 | ||
Percent Insiders 17.97 | Percent Institutions 44.29 |
Analyst Ratings
Rating 4.67 | Target Price 30 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Mediwound Ltd
Company Overview
History and Background
MediWound Ltd., founded in 2000, is a biopharmaceutical company focused on developing, manufacturing, and commercializing novel, cost-effective bio-therapeutic solutions for severe burns, chronic wounds, and other hard-to-treat wounds. They have evolved from focusing solely on enzymatic debridement to expanding their product pipeline and global reach.
Core Business Areas
- EscharEx: A biological product for non-surgical enzymatic debridement of eschar (dead tissue) in severe burn patients. It reduces the need for surgical interventions.
- NexoBrid: The trade name for EscharEx in Europe and other territories. It is marketed by partners outside of the US.
- MW005: A research and development program targeting biological solutions for treating Non-melanoma skin cancers (NMSC).
Leadership and Structure
MediWound's leadership team includes seasoned executives with experience in the pharmaceutical and biotechnology industries. The organizational structure includes departments for research and development, manufacturing, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- NexoBrid/EscharEx: A biological product for non-surgical enzymatic debridement of eschar. While specific global market share data is fragmented and varies by region due to regulatory approvals and market access, it is approved in the US, Europe and other territories. Competitors include traditional surgical debridement and other enzymatic debridement products. Limited market data available.
- MW005: An early-stage product targeting non-melanoma skin cancers (NMSC). No current market share or revenue data available. The competitors are the standard treatments for NMSC which include surgery, radiation and topical treatments. No market data available.
Market Dynamics
Industry Overview
The wound care market is a growing market, driven by an aging population, increasing prevalence of diabetes and obesity, and rising incidence of chronic wounds and burns. The market includes traditional wound care products, advanced wound care products, and biological therapies.
Positioning
MediWound is positioned in the advanced wound care and biologics segment, offering a non-surgical alternative for debridement. Their competitive advantage lies in the potential to reduce surgical interventions and improve patient outcomes.
Total Addressable Market (TAM)
The global wound care market is estimated to be in the billions of dollars. MediWound's TAM is tied to the portion of the market addressable by NexoBrid/EscharEx, which includes severe burns and potentially chronic wounds. Estimates vary, but this portion is significant. The company is positioned to capture a portion of this TAM through market penetration and expansion.
Upturn SWOT Analysis
Strengths
- Novel enzymatic debridement technology
- Potential to reduce surgical interventions
- Approved in US and Europe
- Pipeline of new products (MW005)
Weaknesses
- Reliance on single key product (NexoBrid/EscharEx)
- Dependence on partnerships for commercialization outside the US
- Limited financial resources compared to larger competitors
- Market access challenges and reimbursement hurdles
Opportunities
- Expansion into new geographic markets
- Development of new applications for enzymatic debridement technology
- Strategic partnerships and collaborations
- Positive clinical trial results for MW005
Threats
- Competition from existing and emerging wound care products
- Regulatory hurdles and changes in reimbursement policies
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- Integra LifeSciences (IART)
- Smith & Nephew (SNN)
- Organogenesis Holdings Inc. (ORGO)
Competitive Landscape
MediWound faces competition from established players with broader product portfolios and greater financial resources. Their advantage lies in their novel technology, but they need to overcome market access challenges.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to NexoBrid/EscharEx adoption and sales. Growth trajectory varies depending on market acceptance.
Future Projections: Future growth depends on market penetration, new product development (MW005), and geographic expansion. Analyst estimates are needed to provide specific projections.
Recent Initiatives: Recent initiatives may include clinical trials, regulatory submissions, commercialization efforts, and partnerships.
Summary
MediWound is a biopharmaceutical company with a focus on novel wound care solutions, particularly NexoBrid/EscharEx. While the product offers a non-surgical debridement option with regulatory approvals, the company faces challenges in market penetration and competition. Their dependence on a single product and need for partnerships highlight the need for strategic initiatives. Successful development and commercialization of MW005 will be critical for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may vary. Real-time financial data is required for a more comprehensive analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mediwound Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://www.mediwound.com |
Full time employees 111 | Website https://www.mediwound.com | ||
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.